On top of 348 known job cuts across the organization last year, Roche’s Genentech division laid off an additional 141 ...

The trial showed fenebrutinib reduced disability progression risk by 12% compared to Ocrevus, the only approved PPMS ...

The Philadelphia Department of Commerce awarded $450,000 in matching grants to local life sciences companies in January. The funds will match the amount companies have received from federal Small ...

The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.

Genentech’s $2-billion North Carolina biomanufacturing expansion mid-build tests how power, water and labor constraints are shaping advanced manufacturing construction.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

Genentech's CEO told the Business Times that a massive renovation set to begin in South San Francisco is meant to reimagine ...

Jan 20 (Reuters) - Roche's Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to ...

The 800-person Vacaville site that once produced blockbuster cancer drugs for Genentech is transitioning to new clients under ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...